超声引导经皮内置冷循环射频消融治疗子宫平滑肌瘤的临床研究
|
摘要
第一部分超声引导下经皮冷循环射频消融子宫平滑肌瘤的有效性及安全性研究
目的:通过观察射频消融(RFA)治疗后子宫肌瘤组织的光镜及电镜下的病理变化及术中术后不良反应的症状和体征异常变化,探讨RFA治疗对子宫肌瘤组织结构凝固的范围、坏死程度和副作用及并发症,评价经皮冷循环射频消融治疗子宫肌瘤的疗效及安全性。
方法:2007年3月至2008年1月共有子宫肌瘤患者104例共123个肌瘤,在我院行RFA治疗。随机选择其中30例患者,30个肌瘤分别于治疗前、治疗后即刻行超声引导下穿刺活检。根据取材位置的不同分为:消融灶中央组(A)、消融灶边缘组(B)、消融灶边缘1cm组(C);每组10名患者。标本常规固定,分别行光镜和电镜检查。观察RFA治疗中104例患者的生命体征、氧饱和度、心电监护;治疗后患者生命体征、皮肤毒性反应、治疗后阴道流血,下肢感觉和功能指标,疼痛等情况;观察月经周期,经期,月经量改变相关症状。通过上述观察指标探讨RFA治疗子宫肌瘤的安全性。
结果:RFA治疗后标本光镜显示:A组可见大量均匀红染无结构物质,细胞结构消失;B组可见消融灶边缘平滑肌细胞固缩,细胞间隙扩大;C组可见消融灶边缘可见一明显分界,其内部为典型凝固性坏死。电镜显示:A组见大量髓鞘样结构,细胞轮廓不清,细胞核浓缩,染色质呈团块状;B组可见小血管内红细胞聚集血栓形成,内皮细胞变性;C组肌瘤边缘可见正常的平滑肌细胞及明显的肌丝。RFA治疗过程均顺利按计划完成,治疗过程中监测患者生命体征、心电图、氧饱和度均未出现异常情况。RFA治疗子宫肌瘤不良反应主要为阴道渗出分泌物、少许血液及术后低热(体温38.2±0.4℃,持续1-3天后消失)。极少数病例有小腹疼痛,腹部疼痛程度不重,术后24小时疼痛视觉模拟(Visual analogue scale, VAS)得分3.7±1.1,对患者影响轻微。超声全程监控可避开膀胱及肠管,未出现烧伤及穿孔并发症,早期(3个月内)未发生与治疗相关的副作用及感染、神经损伤等不良事件。
结论:RFA治疗后可以使靶区组织出现凝固性坏死,对周围平滑肌细胞无损伤,证明RFA是一种安全有效的微创治疗子宫平滑肌瘤方法。
第二部分超声引导下经皮冷循环射频消融子宫平滑肌瘤疗效评估的研究
目的:利用超声造影坏死区灌注显影变化评估RFA治疗后的早期疗效,通过对瘤体大小以及临床症状改善的随访,探讨RFA治疗子宫肌瘤的早期疗效评价方法。
方法: 2007年3月至2008年1月共有子宫肌瘤患者104例共123个肌瘤,在我科采用冷却探头(Cool-tipTM)射频消融治疗系统行RFA治疗。治疗后RFA一周内再次行超声造影检查,观察已治疗的肌瘤是否均为无灌注区,有无残留病灶,评价其早期疗效。以后1,3,6,12月行超声随访,计算瘤体均径和体积,并与治疗前进行比较;每半年对患者临床症状进行随访调查,填写子宫肌瘤症状与健康相关生活质量表(UFS-QOL)调查表记录得分,并与治疗前比较。
结果:本研究共104例,随访时间12-26月,平均随访时间19.6±2.4月。治疗后114(92.7%)个肌瘤整体无超声造影剂灌注区,提示没有血流灌注,有9(7.3%)个肌瘤术后造影剂显示仍有部分增强需补充治疗。超声随访结果显示,RFA治疗后治疗后1个月随访瘤体均径即有缩小,与治疗前比较,差异有显著性意义(P<0.05)。RFA治疗后1,3,6,以及12月的肌瘤体积平均缩小率分别为32.4%, 48.3%, 64.1%和76.7%。患者临床症状随访显示RFA治疗对减轻子宫肌瘤引发的临床症状效果明显。RFA治疗后12个月随访显示:104例患者中,69例患者(66.3%)月经过多、痛经、贫血、盆腔疼痛等临床症状完全缓解,42例患者(40.4%)临床症状明显改善,7例患者(6.7%)临床症状无改善,3例患者(2.9%)症状加重。48例患者的子宫肌瘤症状与健康相关生活质量表(UFS-QOL)调查表得分显示术后6月,肌瘤症状得分低于术前,生活质量得分高于术前,差异有显著性意义(P<0.05)。RFA治疗后随访期内,有7例(6.7%)因肌瘤复发进行再次治疗,2例因月经量过多而行子宫切除术,5例再次对复发病灶行RFA。RFA治疗后患者满意度调查结果,93(89.4%)例患者对治疗非常满意,95(91.3%)例患者愿意把这项治疗推荐给朋友亲人。
结论: RFA治疗子宫肌瘤是一种有效的临床治疗方法。
第三部分超声引导下内置冷循环射频消融和微波凝固治疗子宫平滑肌瘤的对比研究
目的:比较超声引导下内置冷循环射频消融和微波凝固治疗子宫肌瘤的临床疗效及副作用。
方法:回顾性研究2006年8月至2008年1月于我中心行RFA和MCT治疗的子宫肌瘤患者的临床资料,其中RFA组104例123个肌瘤,平均直径4.8±1.4cm (3.0-9.93cm),MCT组48例60个肌瘤,平均直径4.7±1.2cm (3.0-7.17cm)。比较两种方法对肌瘤的完全消融率,对临床症状改善的有效率,原位复发率及并发症的发生率。
结果:肌瘤完全消融率RFA组为92.7% (114/ 123),MCT组为86.7% ( 52/ 60 ),两者比χ2 = 1.73,P>0.05,差异无显著性意义。症状改善的有效率为RFA组为90.3 %(94/ 104),MCT组为87.5% ( 42/ 48 ),两者比较χ2 = 0. 29,P>0.05,差异无显著性意义。RFA后7个结节(5. 7 %)局部复发、MCT后9个结节(15 %),P<0.05,两组差异有显著性意义(χ2 = 4.37)。并发症的发生率,两组在阴道排液方面无显著性差异(χ2 = 2.61, P>0.05),术后发热,MCT组要高于RFA组,两组差异有显著性意义(χ2 = 4.04, P<0.05),此外MCT组有1例患者在拔针过程中出现“断针”,另有4例术后出现腹腔积液。
结论:射频消融和微波消融均是微创治疗子宫平滑肌瘤的有效方法,RFA在肌瘤完全消融率和对症状的改善方面与MCT无差异,但是RFA在肌瘤的原位复发率及并发症的发生率上要低于微波凝固治疗。
Part one Effectiveness and safty study on percutaneous ultrasound guided radiofrequency ablation with internally cooled electrod for uterine leiomyoma
Objective: To evaluate the therapeutic efficacy and the safty of uterine fibroid treated with radiofrequency ablation (RFA) by using pathological examination and clinical data.
Methods: From Mar 2007 to Jan 2008, 104 patients with 123 uterine fibroids were treated with RFA in Xijing hospital. From these patients, ultrasound guided needle puncture biopsy was performed in 30 patients one week before and after treatment to analyze RFA therapeutic response pathologically using light microscope and transmission electron microscope. 30 fibroids were divided 3 groups according to location of the puncture: group A (center of lesion), group B (marginal), group C (1-cm away from the margin). Control groups were obtained from puncture biopsy before RFA treatment in the same leiomyoma. We observed patient's vital signs, oxygen saturation of hemoglobin during the procedure, skin toxicity, bleeding, pains paresthesia and disfunction in lower limb following treatment; menstrual cycle, menstruation, menorrhea and hypoestrogen related symptoms after the treatment were evaluated.
Results: Microscopic examination after RFA showed the cellular membranes were ruptured, and the cytoplasm was overflowed in group A, the smooth-muscle cells contracted and the interstitial spaces dilated in group B and an inter-texture or reticulate appearance characteristic of coagulative necrotic in group C. Electron microscopy showed overall debris and implosion cysts in group A, the chromatin in nucleolus of smooth muscle cell formed rounded aggregates, myofilament structure was damaged and endothelial cell death and red blood cell in together in group B, normal nuclei of smooth muscle cells and normal myofilament in group C. All procedures were performed according to the plan and patients were recruited. During the procedures, vital signs, ergocardiogram, and oxygen saturation of hemoglobin were normal. The major adverse Effects of treatment of uterine fibroids by RFA were virginal discharge and light febris (Fever 38.2±0.4℃in 1-3 days post-procedure mostly). The pains of abdomen was light and the score of Visual analogue scale (VAS) were 3.7±1.1 in 24 hours post–procedure. Penetration/burn injuries of the bowel or bladder, sepsis and peritonitis were not reported.
Conclusions: RFA can extracorporeally induce necrosis in target uterine fibroid tissue and surrounding tissue without damage. The evidence directly validates RFA as an effective and safty treatment of uterine fibroid.
Part two Evaluation of therapeutic efficacy on percutaneous ultrasound guided radiofrequency ablation with internally cooled electrod for uterine leiomyoma
Objective: To study the clinical value of real time contrast enhanced ultrasonography (CEUS) in evaluating the therapeutic efficacy and clinical long term results of percutaneous ultrasound guided radiofrequency ablation (RFA) in the treatment of uterine fibroids by following up the volume change and symptom relief after RFA treatment.
Methods: From From Mar 2007 to Jan 2008, 104 consecutive patients with 123 uterine fibroids were treated with RFA. Immediate therapeutic effects were assessed at follow-up with CEUS and CDFI. All patients were followed up to observe long-term therapeutic effects. Leiomyoma mean diameters, volumes and reduction rates 1, 3, 6 and 12 months after RFA treatment were calculated and compared by using one-way ANOVA and Student-Newman-Keuls tests.
Improvement in myoma-related symptoms and impacton quality of life were assessed using a validated questionnaire (UFS-QOL).
Results: All patients were followed up for 12-26 months (mean, 19.6±2.4 months). After the RFA, on the CEUS, complete tumor ablation was observed in 92.7% of the 114 uterine leiomyomas and residual unablated fibroids were found in 9 leiomyomas (7.3%). Follow-up images showed absence or reduction of blood supply in the lesions after RFA. Results showed that the mean diameter began to decrease one month after RFA, Median reductions in tumor size as a percentage of initial fibroid volume at 1, 3, 6, and 12 months after RFA treatment were 32.4%, 48.3%, 64.1% and 76.7% respectively. 40.4% of women in our study declared significant relief from previous symptoms 12 months after RFA treatment and 66.3% reported completely asymptomatic after RFA treatment. One year after the procedure, 7 women (6.7%) were recurrence of fibroid-related symptoms. Quality-of-life measures showed significant and durable improvement compared with baseline.
Conclusions: RFA ablation appears to be an effective treatment of uterine leiomyomain reducing the volume and treating the symptoms.
Part three Ultrasound guided ablation treatments for uterine leiomyoma: a comparison between radiofrequency ablation and microwave coagulation treatment
Objective: Comparing the value in clinical practice of ultrasound guided ablation therapies for uterine leiomyoma between using radiofrequency ablation and microwave coagulation treatment.
Methods: From Aug 2006 to Jan 2008, percutaneous radiofrequency (RFA) was used to treat 104 cases with 123 fibroids, with a diameter of 4.8±1.4cm (3.0-9.93cm), percutaneous microwave coagulation therapy (MCT) was employed to treat 48 cases with 60 fibroids, with a diameter of 4.7±1.2cm (3.0-7.17cm). To compare RFA and MCT in local ablation effect, effective rate of improve symptoms, recurernce rate in local and the incidence of complications.
Results: The fibroid completely ablation rate was 92.7% (114/123) in RFA and 86.7% (52/60) in MCT, which showed no significant difference in statistics(χ2 = 0. 17, P>0.05). The effective rate of improve symptoms was 90.3 %(94/104) in RFA, 87.5% ( 42/48 ) in MCT, which showed no significant difference in statistics(χ2 = 0. 29,P>0.05). The recurernce rate was 5.7% (7/123) in RFA, 15% (9/60) in MCT, which showed significant difference in statistics(χ2= 4.37,P<0.05). There was also no difference in vaginal between the two ablations (x2= 2.61, P>0.05), the light fever was 7.7% (8/104) in RFA and 18.8% (9/48) in MCT, which showed significant difference (χ2 = 4.04, P<0.05). In addition, one microwave antenna was broken in the pull needle.
Conclusions: RFA is contemporary ideal therapeutic approaches of interventional ultrasound for uterine leiomyoma. The rate of recurrence and complication were lower in RFA compare with MCT.
目的:通过观察射频消融(RFA)治疗后子宫肌瘤组织的光镜及电镜下的病理变化及术中术后不良反应的症状和体征异常变化,探讨RFA治疗对子宫肌瘤组织结构凝固的范围、坏死程度和副作用及并发症,评价经皮冷循环射频消融治疗子宫肌瘤的疗效及安全性。
方法:2007年3月至2008年1月共有子宫肌瘤患者104例共123个肌瘤,在我院行RFA治疗。随机选择其中30例患者,30个肌瘤分别于治疗前、治疗后即刻行超声引导下穿刺活检。根据取材位置的不同分为:消融灶中央组(A)、消融灶边缘组(B)、消融灶边缘1cm组(C);每组10名患者。标本常规固定,分别行光镜和电镜检查。观察RFA治疗中104例患者的生命体征、氧饱和度、心电监护;治疗后患者生命体征、皮肤毒性反应、治疗后阴道流血,下肢感觉和功能指标,疼痛等情况;观察月经周期,经期,月经量改变相关症状。通过上述观察指标探讨RFA治疗子宫肌瘤的安全性。
结果:RFA治疗后标本光镜显示:A组可见大量均匀红染无结构物质,细胞结构消失;B组可见消融灶边缘平滑肌细胞固缩,细胞间隙扩大;C组可见消融灶边缘可见一明显分界,其内部为典型凝固性坏死。电镜显示:A组见大量髓鞘样结构,细胞轮廓不清,细胞核浓缩,染色质呈团块状;B组可见小血管内红细胞聚集血栓形成,内皮细胞变性;C组肌瘤边缘可见正常的平滑肌细胞及明显的肌丝。RFA治疗过程均顺利按计划完成,治疗过程中监测患者生命体征、心电图、氧饱和度均未出现异常情况。RFA治疗子宫肌瘤不良反应主要为阴道渗出分泌物、少许血液及术后低热(体温38.2±0.4℃,持续1-3天后消失)。极少数病例有小腹疼痛,腹部疼痛程度不重,术后24小时疼痛视觉模拟(Visual analogue scale, VAS)得分3.7±1.1,对患者影响轻微。超声全程监控可避开膀胱及肠管,未出现烧伤及穿孔并发症,早期(3个月内)未发生与治疗相关的副作用及感染、神经损伤等不良事件。
结论:RFA治疗后可以使靶区组织出现凝固性坏死,对周围平滑肌细胞无损伤,证明RFA是一种安全有效的微创治疗子宫平滑肌瘤方法。
第二部分超声引导下经皮冷循环射频消融子宫平滑肌瘤疗效评估的研究
目的:利用超声造影坏死区灌注显影变化评估RFA治疗后的早期疗效,通过对瘤体大小以及临床症状改善的随访,探讨RFA治疗子宫肌瘤的早期疗效评价方法。
方法: 2007年3月至2008年1月共有子宫肌瘤患者104例共123个肌瘤,在我科采用冷却探头(Cool-tipTM)射频消融治疗系统行RFA治疗。治疗后RFA一周内再次行超声造影检查,观察已治疗的肌瘤是否均为无灌注区,有无残留病灶,评价其早期疗效。以后1,3,6,12月行超声随访,计算瘤体均径和体积,并与治疗前进行比较;每半年对患者临床症状进行随访调查,填写子宫肌瘤症状与健康相关生活质量表(UFS-QOL)调查表记录得分,并与治疗前比较。
结果:本研究共104例,随访时间12-26月,平均随访时间19.6±2.4月。治疗后114(92.7%)个肌瘤整体无超声造影剂灌注区,提示没有血流灌注,有9(7.3%)个肌瘤术后造影剂显示仍有部分增强需补充治疗。超声随访结果显示,RFA治疗后治疗后1个月随访瘤体均径即有缩小,与治疗前比较,差异有显著性意义(P<0.05)。RFA治疗后1,3,6,以及12月的肌瘤体积平均缩小率分别为32.4%, 48.3%, 64.1%和76.7%。患者临床症状随访显示RFA治疗对减轻子宫肌瘤引发的临床症状效果明显。RFA治疗后12个月随访显示:104例患者中,69例患者(66.3%)月经过多、痛经、贫血、盆腔疼痛等临床症状完全缓解,42例患者(40.4%)临床症状明显改善,7例患者(6.7%)临床症状无改善,3例患者(2.9%)症状加重。48例患者的子宫肌瘤症状与健康相关生活质量表(UFS-QOL)调查表得分显示术后6月,肌瘤症状得分低于术前,生活质量得分高于术前,差异有显著性意义(P<0.05)。RFA治疗后随访期内,有7例(6.7%)因肌瘤复发进行再次治疗,2例因月经量过多而行子宫切除术,5例再次对复发病灶行RFA。RFA治疗后患者满意度调查结果,93(89.4%)例患者对治疗非常满意,95(91.3%)例患者愿意把这项治疗推荐给朋友亲人。
结论: RFA治疗子宫肌瘤是一种有效的临床治疗方法。
第三部分超声引导下内置冷循环射频消融和微波凝固治疗子宫平滑肌瘤的对比研究
目的:比较超声引导下内置冷循环射频消融和微波凝固治疗子宫肌瘤的临床疗效及副作用。
方法:回顾性研究2006年8月至2008年1月于我中心行RFA和MCT治疗的子宫肌瘤患者的临床资料,其中RFA组104例123个肌瘤,平均直径4.8±1.4cm (3.0-9.93cm),MCT组48例60个肌瘤,平均直径4.7±1.2cm (3.0-7.17cm)。比较两种方法对肌瘤的完全消融率,对临床症状改善的有效率,原位复发率及并发症的发生率。
结果:肌瘤完全消融率RFA组为92.7% (114/ 123),MCT组为86.7% ( 52/ 60 ),两者比χ2 = 1.73,P>0.05,差异无显著性意义。症状改善的有效率为RFA组为90.3 %(94/ 104),MCT组为87.5% ( 42/ 48 ),两者比较χ2 = 0. 29,P>0.05,差异无显著性意义。RFA后7个结节(5. 7 %)局部复发、MCT后9个结节(15 %),P<0.05,两组差异有显著性意义(χ2 = 4.37)。并发症的发生率,两组在阴道排液方面无显著性差异(χ2 = 2.61, P>0.05),术后发热,MCT组要高于RFA组,两组差异有显著性意义(χ2 = 4.04, P<0.05),此外MCT组有1例患者在拔针过程中出现“断针”,另有4例术后出现腹腔积液。
结论:射频消融和微波消融均是微创治疗子宫平滑肌瘤的有效方法,RFA在肌瘤完全消融率和对症状的改善方面与MCT无差异,但是RFA在肌瘤的原位复发率及并发症的发生率上要低于微波凝固治疗。
Part one Effectiveness and safty study on percutaneous ultrasound guided radiofrequency ablation with internally cooled electrod for uterine leiomyoma
Objective: To evaluate the therapeutic efficacy and the safty of uterine fibroid treated with radiofrequency ablation (RFA) by using pathological examination and clinical data.
Methods: From Mar 2007 to Jan 2008, 104 patients with 123 uterine fibroids were treated with RFA in Xijing hospital. From these patients, ultrasound guided needle puncture biopsy was performed in 30 patients one week before and after treatment to analyze RFA therapeutic response pathologically using light microscope and transmission electron microscope. 30 fibroids were divided 3 groups according to location of the puncture: group A (center of lesion), group B (marginal), group C (1-cm away from the margin). Control groups were obtained from puncture biopsy before RFA treatment in the same leiomyoma. We observed patient's vital signs, oxygen saturation of hemoglobin during the procedure, skin toxicity, bleeding, pains paresthesia and disfunction in lower limb following treatment; menstrual cycle, menstruation, menorrhea and hypoestrogen related symptoms after the treatment were evaluated.
Results: Microscopic examination after RFA showed the cellular membranes were ruptured, and the cytoplasm was overflowed in group A, the smooth-muscle cells contracted and the interstitial spaces dilated in group B and an inter-texture or reticulate appearance characteristic of coagulative necrotic in group C. Electron microscopy showed overall debris and implosion cysts in group A, the chromatin in nucleolus of smooth muscle cell formed rounded aggregates, myofilament structure was damaged and endothelial cell death and red blood cell in together in group B, normal nuclei of smooth muscle cells and normal myofilament in group C. All procedures were performed according to the plan and patients were recruited. During the procedures, vital signs, ergocardiogram, and oxygen saturation of hemoglobin were normal. The major adverse Effects of treatment of uterine fibroids by RFA were virginal discharge and light febris (Fever 38.2±0.4℃in 1-3 days post-procedure mostly). The pains of abdomen was light and the score of Visual analogue scale (VAS) were 3.7±1.1 in 24 hours post–procedure. Penetration/burn injuries of the bowel or bladder, sepsis and peritonitis were not reported.
Conclusions: RFA can extracorporeally induce necrosis in target uterine fibroid tissue and surrounding tissue without damage. The evidence directly validates RFA as an effective and safty treatment of uterine fibroid.
Part two Evaluation of therapeutic efficacy on percutaneous ultrasound guided radiofrequency ablation with internally cooled electrod for uterine leiomyoma
Objective: To study the clinical value of real time contrast enhanced ultrasonography (CEUS) in evaluating the therapeutic efficacy and clinical long term results of percutaneous ultrasound guided radiofrequency ablation (RFA) in the treatment of uterine fibroids by following up the volume change and symptom relief after RFA treatment.
Methods: From From Mar 2007 to Jan 2008, 104 consecutive patients with 123 uterine fibroids were treated with RFA. Immediate therapeutic effects were assessed at follow-up with CEUS and CDFI. All patients were followed up to observe long-term therapeutic effects. Leiomyoma mean diameters, volumes and reduction rates 1, 3, 6 and 12 months after RFA treatment were calculated and compared by using one-way ANOVA and Student-Newman-Keuls tests.
Improvement in myoma-related symptoms and impacton quality of life were assessed using a validated questionnaire (UFS-QOL).
Results: All patients were followed up for 12-26 months (mean, 19.6±2.4 months). After the RFA, on the CEUS, complete tumor ablation was observed in 92.7% of the 114 uterine leiomyomas and residual unablated fibroids were found in 9 leiomyomas (7.3%). Follow-up images showed absence or reduction of blood supply in the lesions after RFA. Results showed that the mean diameter began to decrease one month after RFA, Median reductions in tumor size as a percentage of initial fibroid volume at 1, 3, 6, and 12 months after RFA treatment were 32.4%, 48.3%, 64.1% and 76.7% respectively. 40.4% of women in our study declared significant relief from previous symptoms 12 months after RFA treatment and 66.3% reported completely asymptomatic after RFA treatment. One year after the procedure, 7 women (6.7%) were recurrence of fibroid-related symptoms. Quality-of-life measures showed significant and durable improvement compared with baseline.
Conclusions: RFA ablation appears to be an effective treatment of uterine leiomyomain reducing the volume and treating the symptoms.
Part three Ultrasound guided ablation treatments for uterine leiomyoma: a comparison between radiofrequency ablation and microwave coagulation treatment
Objective: Comparing the value in clinical practice of ultrasound guided ablation therapies for uterine leiomyoma between using radiofrequency ablation and microwave coagulation treatment.
Methods: From Aug 2006 to Jan 2008, percutaneous radiofrequency (RFA) was used to treat 104 cases with 123 fibroids, with a diameter of 4.8±1.4cm (3.0-9.93cm), percutaneous microwave coagulation therapy (MCT) was employed to treat 48 cases with 60 fibroids, with a diameter of 4.7±1.2cm (3.0-7.17cm). To compare RFA and MCT in local ablation effect, effective rate of improve symptoms, recurernce rate in local and the incidence of complications.
Results: The fibroid completely ablation rate was 92.7% (114/123) in RFA and 86.7% (52/60) in MCT, which showed no significant difference in statistics(χ2 = 0. 17, P>0.05). The effective rate of improve symptoms was 90.3 %(94/104) in RFA, 87.5% ( 42/48 ) in MCT, which showed no significant difference in statistics(χ2 = 0. 29,P>0.05). The recurernce rate was 5.7% (7/123) in RFA, 15% (9/60) in MCT, which showed significant difference in statistics(χ2= 4.37,P<0.05). There was also no difference in vaginal between the two ablations (x2= 2.61, P>0.05), the light fever was 7.7% (8/104) in RFA and 18.8% (9/48) in MCT, which showed significant difference (χ2 = 4.04, P<0.05). In addition, one microwave antenna was broken in the pull needle.
Conclusions: RFA is contemporary ideal therapeutic approaches of interventional ultrasound for uterine leiomyoma. The rate of recurrence and complication were lower in RFA compare with MCT.
引文
1. Buttram VC, Reier RC. Uterine leiomyomata: etiolog, symptomatolog, management. Fertil Seril. 1981;36:433-45.
2. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94:435-38.
3. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly gorwing leiomyoma. Obstet Gynecol. 1994;83:414-18
4. Otubu JA, Buttram VC, Besch NF, Besh PK. Unconjugated Steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol. 1982;143:130-3.
5. Ymarnoto T, Takamoir K, Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res. 1984,16:678-9
6. Brandon DD, Erichson TE, Keenna EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton GM. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995;80:1876-81.
7. Ichimura T, Kawarmura N, Ito F, Minakuchi K, Tsujimura A, Umesaki N, Ogita S. Corerlation between the growth of uterine leiomyomata and estrogen and progensterone receptor content in needle biopsy specimens. Fertil Steril. 1998;70:967-71.
8. Lamminen S, Rantalal, Helin H, Rorarius M, Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gymecol Obstet Invest. 1992;34:111-4.
9. Kawaguchi K, Fuji S, Konishil, Nanbu Y, Nonogaki H, Mori T. Mitoticactivity in uterine leiomyomas during the menstrul cycle. Am J Obstet Gynecol. 1989;160:637-41.
10. Fujii S, Nakashima N, Okamura H. Progesterone-induced smooth muscle-like cells in the subperitoneal nodules produced by estrogen. Experimental approach to leiomyomatosis petronealis disseminate. Am J Obstet Gynecol. 1981;139(2):164-172.
11. Aornica SM, Katzenellenbogen Bs. Porgestrone receptor regulation in uterine cells: Stimulation by estrogen, cuclic adenosine3’5’-monophosphate, and insulin-like growth facter I and suppression by antiestrogens and protein kinase inhabitors. Endocrinoloy 1991;128:2045-52.
12. Yet J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF recetor demonstrable in monolayer cell cultures of myometria and leiomyoma. Fertil Steril. 1991;56:997-1000.
13.郁雯,姜英,王晓玲.子宫肌瘤组织雌孕激素受体和表皮生长因子受体研究肿瘤研究与临床2002;14(4):234-236.
14.甘晓平,李卫平,陈珠萍.表皮生长对子宫肌瘤发生发展的影响.中国实用妇科与产科杂志2000;16(11):677-678.
15. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine orparacrine growth factor for human myometial and leiomyoma cells. Gynecol Obstet Invest. 1999;48:127-132.
16. Gover A, Mukunda BN. Humoral hypercalcemia associated with a uterine fibroid letter. Ann Intern Med. 1999;130(8):702.
17. Nohara A, Ohmichi M, Koike K. Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. Biochem Biophys Res Commun. 1997;238(2):473-474.
18. Ohbuchi H, Nagai K, Yamaguchi M, Ikenoue T, Mori N, Kitamura K, ArakiS, Toshimori K. Endothelin-1 and big endothelin-1 increase in human endometerium during menstruation. Am J Obstet Gynecol. 1995;173(5):1483-90.
19. Pekonen F, Nyman T, Rutnaen EW. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. Mol Cell Endocrino. 1994;103:165-170.
20. Clevenger-Hoeft M, Syrop CH, Stovall DW, Van Voorhis BJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999;94(4):516-20.
21. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Repord Update 1996;2(4):295-306.
22. Stovall JG, Gussak LS. Dysphagia and Chronic Mental Illness: Looking Beyond Hysteria and Broadening the Psychiatric Differential Diagnosis. Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):143-144.
23. Coutinho EM, Maia HS. The contractile response of the human uterus, fallopian tubes, and ovary to prostaglandins in vivo. Fertil Steril. 1971 Sep;22(9):539-43.
24. Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol. 1970 ;23(8):676-80.
25. Strobelt N, Ghidini A, Cavallone M, Pensabene I, Ceruti P, Vergani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med. 1994;13(5):399-401.
26. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol. 2000;95(5):764-9.
27. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinicalpresentation. Am J Obstet Gynecol. 1993;168(1 Pt 1):180-3.
28.徐苓.子宫肌瘤非手术治疗的理论基础及适应症.中国实用妇科与产科杂志2001;17(3):129.
29.李力,子宫肌瘤的性激素治疗.中国实用妇科与产科杂志2001;17 (3):132
30. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993; 76(2):513-517
31. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746-51
32. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women withuterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109:1097-108.
33. Rutgers JL, Spong CY, Sinow R, Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol. 1995;86:386-8.
34. Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyoma in Japanese women. Fertil Steril. 1992;58:66-71
35. Lee WL, Yuan CC, Wang PH. Positron emission tomography and uterine leiomyomas. Gynecol Oncol. 2007;107:593-4.
36. Lee WL, Liu RS, Yuan CC, Chao HT, Wang PH. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography. Fertil Steril. 2001;75:638-9.
37. Ito F, Kawamura N, Ichimura T, Tsujimura A, Ishiko O, Ogita S. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment. Fertil Steril. 2001;75:125-30
38. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993;24:1073-7.
39. Higashijima T, Kataoka A, Nishida T, Yakushiji M. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 1996;68:169-73.
40. Cheng MH, Yu BK, Chang SP, Wang PH. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. J Chin Med Assoc. 2005;68:307-14.
41. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril. 1992;58:413-5.
42. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol. 1994;8:215-22.
43. Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 1990;53:1018-23.
44. Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women-focus on the breast. Taiwan J Obstet Gynecol. 2007;46:127-34.
45. Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonists. Fertil Steril. 1993;60:642-6.
46. De Blok S, Oberye J. Rapid reduction of leiomyoma volume during treatment with the GnRH-antagonist ganirelix. Gynecol Endocrinol. 2001;15:22.
47. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-62.
48. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term Use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5:235-41.
49. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;(4):CD002126.
50. Habelt K, Brosche T, Riedel HH. Symptoms of ovarian failure after hysterectomy in premenopausal women. A retrospective study based on postoperative perception of 245 women. Zentralbl Gynakol 1996; 118(4):206-212.
51. Eltabbakh GH. Effect of surgeon experience on the surgical outcome of laparoscop in surgery for women with endometrial cancer. Gynecol Oncol. 2000;78(1):58-61.
52. Falcone T, Paraiso MF, Mascha E. Prospective random ized clinical trial of laparoscop ically assisted vaginal hysterectomy versus total abdom inal hysterectomy. Am J Obstet Gynecol. 1999;180(4):955-962.
53. Hallez JP. Single-stage total hysteroscopic myomectomies: indications, techniques, and results. Fertil Steril. 1995;63(4):703-8.
54. Polena V, Mergui JL, Perrot N, Poncelet C, Barranger E, Uzan S. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):232-7.
55. Ravina J H, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A, Merland JJ. Arterial embolization to treat uterine myomata. Lancet 1995;346(8976):671-2.
56. Ravina J H, Bouret J H, Ciraru-Vigneron N, Repiquet D, Herbreteau D, Aymard A, le Dreff O, Merland JJ, Ferrand J. Recourse to particular arterial embolization in the treatment of some uterine leiomyoma. Bull Acad Natl Med. 1997;181 (2):233-43.
57. Worthington-Kirsch RL, Popky GL, Hutchins FL. Uterine arterial embolization for the management of leiomyomas: quality-of-life assessment and clinical response. Radiology 1998;208:625-9.
58. Vashisht A, Studd J, Carey A, Burn P. Fatal sepicaemia after fibroid embolisation. Lancet 1999;354 (9175):307-308
59. Dover RW, Torode HW, B riggs GM. Uterine artery embolisation for symptomatic fibroids. Med J Aust. 2000;172(5): 233-236.
60.杨华光,井红鸽,李冰.阔韧带内巨大子宫肌瘤行介入栓塞术导致卵巢坏死的诊治.医学研究生学报2003;16(12): 956-959.
61. Worthington-Kirsch RL, Andrews RT, Siskin GP, Shlansky-Goldberg R, Lipman JC, Goodwin SC, Bonn J, Hovsepian DM. Uterine fibroid embolization: technical aspects. Tech Vasc Interv Radiol. 2002;5 (1):17-34.
62. Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. Laparoscopic leiomyoma coagulation. Am Assoc Gynecol Laparoscop 1996;3(4Suppl):S39
63. Goldfarb H.Laparoscopic coagulation of myoma (myolysis).Obstet Gynecol Clin North Am. 1995;22(4):807-819.
64. Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopi electromyolysis. Am Assoc Gynecol Laparoscop. 1998;5(3):289-292.
65.白广德,谢爱玲,谢桂珍.腹腔镜引导经皮氩氦靶向治疗子宫肌瘤5例.广西中医学院学报2004;7(1):32-34.
66.陈湘云,罗启东.微波治疗脱入阴道的子宫黏膜下肌瘤.中华妇产科1997,32(1).
67.刘平,张俊发,戴秋玲.微波治疗宫颈肌瘤.中华物理医学与康复杂志2000, 22 (6):382.
68. Lynn JG, Fry WJ, Meyers R. The biological application focused ultrasonic waves. Science. 1942;96(2483):119-120.
69. Wu F, Wang ZB, Zhu H, Extracorpo real high in tensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Res Treat. 2005;92: 5160.
70. Uchida T, Baba S, Irie A. Tran srectal high intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyo kika Kiyo 2005;51: 651-658.
71. Ren XL, Zhou XD, Zhang J, He GB, Han ZH, Zheng MJ, Li L, Yu M, Wang L. Extracorporeal Ablation of Uterine Fibroids with High-Intensity Focused Ultrasound Imaging and Histopathologic Evaluation. J Ultrasound Med 2007; 26:201-12.
72. Hynynen K, Chung AH, Colucci V, Jolesz FA. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol, 1996; 22(2):193-201.
73.谢红宁,车艳玲,刘杰.超声引导下瘤内无水乙醇注射治疗子宫肌瘤的初步研究.中国实用妇科与产科杂志,2000,16(4):225.
74. Niu H, Simari RD, Zimmermann EM and Christman GM (1998) Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet Gynecol 91,735-740.
75. Rai R, Barakat O, Rose J, Manas D. Role of radiofrequency ablation in multimodality management of unresectable liver tumours. J Gastrointest Surg. 2003;7:263-264.
76. Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, Griffey SM. Radiofrequeney ablation of breast caneer: first report of emerging technology. Arch Surg. 1999;134(10):064-1068.
77.乔清理.组织消融一般模型的建立与其温度分布的分析与解析计算中国生物医学.工程学报, 2002;21(1):74-78
78. Diekso J, Calder wood S, Storm F. Thermosensitivity of neoplastic in tissues in vivo. Hall Medical Publisher l983,63-140.
79. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227(4):559-65.
80. McGahan JP, Griffery SM, Schneider PD, Brock JM, Jones CD, Zhan S.. Radiofrequency electrocautery ablation of mammary tissue in swine. Radiology. 2000;217:471-6.
81. Cuschieri A, Bracken J, Boni L. Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumors. Endoscopy. 1999;31(4):318-21.
82. Pearson SA, Lzzo F, Fleming RY. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178:592-9.
83. Walther MM, Shawker TH, Libutti SK. A phase II study of radiofrequency interstitial tissue ablation of localized renal tumors. J Urol. 2000;163:1424.
84. Lencioni R, Goletti O, Amillotta N. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial. Eur Radiol 1998;8(7):1205-1211.
85. de Baere T, Denys A, Wood BJ. Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol 2001;176:187–192
86. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169–S171
87. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangio carcinomavariants. J Gastroenterol Hepatol 2002;17(4):401-405.
88. Bowles BJ, Machi J, Limm WM. Safety and efficacy of radio-frequency thermal ablation in advanced liver tumors. Arch Surg 2001;136:864-869.
89. Gillams AR, Lees WR. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:656-661.
90. Parikh AA, Curley SA, Fornage BD. Radiofrequency ablation of hepatic metastases. Semin Oncol 2002;29(2):168-182.
91. McGahan JP, Dodd GD. Radiofrequency ablation of the liver: current status. Am J Roent 2001;176:3-16.
92. Topham C, Adam R. Oncosurgery: a new reality in metastatic colorectal carcinoma. Semin Oncol 2002;29(5 Suppl 15):3-10.
93. McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990;25:267-270.
94. Rossi S, Stasi MD, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CTS, ilverman DE, Buscarini L. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR 1996;167:759-768.
95. Rossi S, Buscarini E, Garbagnati F, Stasi MD, Quaretti P, Rago M, Zangrandi A, Andreola S, Silverman D, Bsucarini L. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR 1998;170:1015-1022.
96. Buscarini L, Buscarini E, Stasi MD, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 2001;11:914-921.
97. Rossi S, Garbagnati F, RosaL, Azzaretti A, Belloni G, Quaretti P. Radiofrequency thermal ablation for treatment of hepatocellular carcinoma. Int J Clin Oncol 2002;7:225-235.
98. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-661.
99. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-166.
100.D'Ippolito G, Goldberg SN. Radiofrequency ablation of hepatic tumors. Tech Vasc Interv Radiol 2002;5(3):141-155.
101.Goldberg SN, Solbiati L. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001;34:609-611.
102.Livraghi T. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001;34:608-611.
103.Livraghi T, Solbiati L, Meloni MF. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
104.Jacomides L, Ogan K, Watumull L. Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol 2003;169:49-53.
105.Pavlovich CP, Walther MM, Choyke PL. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol 2002;167:10-5.
106.Gervais DA, McGovern FJ, Arellano RS. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003;226:417-424.
107.Pinto CH, Taminiau AH, Vanderschueren GM. Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol 2002;179:1633-1642.
108.Vanderschueren GM, Taminiau AH, Obermann WR. Osteoid osteoma: clinical results with thermocoagulation. Radiology 2002;224:82-86.
109.Callstrom MR, Charboneau JW, Goetz MP. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 2002;224:87-97.
110.Callstrom MR, Charboneau JW, Goetz MP. Percutaneous CT/US-guided radiofrequency ablation of painful metastases involving bone: a multicenter international study. Radiol Soc North Am Annual Meeting. 2002
111.Sewell PE Jr. Percutaneous radiofrequency ablation of primary and secondary pulmonary malignancies using CT guidance. Radiol Soc North Am Annual Meeting. 2002
112.Lee J, Jin G, Lee Y. CT-guided transthoracic radiofrequency ablation formedically inoperable stage I non-small cell lung cancer. Radiol Soc North Am Annual Meeting. 2002
113.Rose SC, Fotoohi M, Levin DL. Cerebral microembolization during radiofrequency ablation of lung malignancies. J Vasc Interv Radiol. 2002;13:1051-1054.
114.Izzo F, Thomas R, Delrio P. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer. 2001;92:2036-2044.
115.Wood BJ, Abraham J, Hvizda JL. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554-560
116.Pacak K, Fojo T, Goldstein DS. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001;93:648-649.
117.Wu JS, Wong R, Johnston M. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594-605.
118.冯忻,刘海鹰,赵营,谭小军,陈力排.多弹头射频治疗妇科肿瘤的尝试.广东医学. 2001; 22 (8):692-693.
119.邱学华,邓黎,李月英,吴蕾,王新玲,高静.射频消融子宫肌瘤的病理变化.第四军医大学学报. 2003;24(14):1301-1303.
120.曹树军,曹淑彬,陈双郧,杨卫疆,张春莲,王梅,何琳,王斌.射频消融治疗子宫肌瘤的安全性研究.郧阳医学院学. 2002;21(3):132-135.
121.Bergam ini V, Ghezzi F, Crom i A, Bellini G, Zanconato G, Scarperi S, Franchi M. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. Am J Obstet Gynecol. 2005;192(3):768-773.
122.汤晓秋,刘广月.射频消融治疗子宫肌瘤196例报告.江苏大学学报(医学版). 2003;13 (4): 340-341.
123.宋雯霞,罗新,吴秀枝,常明伟.射频消融对子宫肌瘤组织病理变化及雌、孕激素受体表达的影响.郧阳医学院学报. 2002,21(5):257-260.
124.Phipps JH, Lewis BV, Roberts T, Prior MV, Hand JW, Elder M, Field SB. Treatment of functional menorrhagia by radiofrequeney-induced thermal endometrial ablation. Lancet, 1990;335(8686):374-6.
125.Phipps JH, Lewis BV, Prior MV, Roberts T. Experimental and clinical studies with radiofrequency-induced thermal endometrial ablation for functional menorrhagia: Obstet Gyneeol. 1990;76(5Ptl):876-81.
126.phipps JH, Smith T, Dymek P, Hesp R, Lewis BV. Validation of a method of treating menorrhagia by endometrial ablation. Clin Phys Physiol Meas.1992;13(3):273-80.
127.Silvemagel SW, Harshbarger KE, Shevlin DW. Postoperative granulomas of the endometrium: histological features after endometrial ablation. Ann Diagn Pathol.1997;1(2):82-90.
128.Dequesne JH, Gallinat A, Garza-Lea JG, Sutton CJ, van der Pas HF, Wamsteker K, Chandler JG. l. Int J Fertil Womens Med. 1997;42(5):311-18.
129.宋学红,迟闺珠,于秀梅,高居中.射频消融术治疗宫颈糜烂的疗效观察.中华物理医学杂志. 1996,18(3):155-156.
130.王共先,熊礼生,梁绮霞,鲁伟明,刘群.腔内射频热治疗慢性宫颈炎.江西医学. 1998, 23(l):3-4.
131.李庆丰,区海,钟沼涛.应用射频治疗子宫颈糜烂.中华妇产科杂志. 2000, 35(3)184-185.
132.BianeoV, Erba P, Remotti G. Florid vulvar condylomatosi Comparison of therapeutic schedules. Ann Ostet Gineeol Med perinat, 1991;112(4):247-56
133.Zaza M, Grassi , Mardjonovic A, Valli E, FarnéC, Romanini C. The use of eleetrosurgery in the treatment of extra-cervical genital condylomatosis, Minerva Gineeol, 1998;50(9):367-71.
134.Challenor R,Alexander I. A five-year audit of the treatment of extensive anogenital Warts by day case eleetrosurgery under general anaesthesia. Int J STD AIDS. 2002;13(11):786-9.
135.Manganill PD, Sueoka BL, Valntine DR. A bipolar radiofrequency catheter fails to occlude a feline uterine horn: A model for fallopian tube occlusion. Am Assoe Gynecol Laparosc. 1998;5(3):269-73.
136.Hurst BS,Ryan T,Thomsen S,Lawes K. ComPuter-controlled bipolar endotubal Sterilization is sueeessful in a rabbit model. Fertil Steril. 1999,71(4):765-70.
137.Kuscu E, Duran HE, Zeyneloglu HB, Demirhan B, Bagis T, Saygili E. The effect surgical sterilization on ovarian function: a rat model. Eur J Obstet Gynecol Reprod Biol. 2002;100(2):204-7.
138.Buscarini L, Buscarini E, Stasi MD, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11:914-921.
139.Livraghi T, Solbiati L, Meloni MF. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
140.Fontana RJ, Hamidullah H, Nghiem H. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl Surg. 2002;8:1165-1174.
141.Wiersinga WJ, Jansen MC, Straatsburg IH. Lesion progression with time and the effect of vascular occlusion following radiofrequency ablation ofthe liver. Br J Surg. 2003;90:306-312.
142.Yamasaki T, Kurokawa F, Shirahashi H. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer. 2002;95:2353-2360.
143.Goldberg SN, Ahmed M, Gazelle GS. Radio-frequency thermal ablation with NaCl solution injection: effect of electrical conductivity on tissue heating and coagulation-phantom and porcine liver study. Radiology. 2001;219:157-165.
144.Kitamoto M, Imagawa M, Yamada H. Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without embolization. Am J Roentgenol. 2003;181:997-1003.
145.Chopra S, Dodd GD 3rd, Chintapalli KN. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol.2001;177:381-387.
146.Anderson GS, Brinkmann F, Soulen MC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192-197.
147.Cioni D, Lencioni R, Rossi S. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power doppler sonography to assess treatment outcome. AJR Am J Roentgenol. 2001;177:783-788.
148.黄荷风,胡林姿.子宫内分泌.外医学妇产科分. 1994,21(5):263-266.
149.Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC. Radiofrequency ablation of solid tumors. Cancer. 2001;7(2)95-102.
150.曹泽毅,主编,中华妇产科学,第1版北京:人民卫生出版社. 1999:1802
151.Bergqvist A, Nejaty H, Fr?ysa B, Bruse C, Carlberg M, Sj?blom P, S?der O. Production of interleukinslbeta,6 and 8 and tumor necrosis factor alpha in separated and cultured endometrial and endometriotic stromal and epithelial cells. Gynecol Obstet Invest. 2000;50(1):1-6.
152.Witz CA, Takahashi A, Montoya-Rodriguez IA, Cho S, Schenken RS. Expression of the alpha 2 beal and alpha3 betal integrins at the surface of mesothelial cells: a potential attachment site of endometrial cell, Fertil steril. 2000;74(3):579-584.
153.黄舒娥,刘运科,赵慧娟,龚慧芳.全子宫切除术对妇女血脂、血液流变学的影响.中国现代医学杂志. 1997;7(10):18-19.
154.范引侠,吴静,彭慧霞.子宫切除术后远期卵巢功能变化的临床观察.陕西医学杂志. 2002;31(6):392-394.
155.邓敏,王祥珍.子宫肌瘤全子宫切除术后性心理障碍研究.湖北医科大学学报. 2000;21(3):236-237.
156.Wang GX, Xion LS, Peng SP. Pathological changes and changes in expression of PSA, SR of prostatic tissue induce by radio-frequency hyperthermia. Chin J Urol 1997;18(11):643-6.
157.Qiao QL, Wang MS, Zhu YS. A general model for human tissue ablation and its analytical calculation of temperature distribution. China J Biomed Eng. 2002;21(1):74-8.
158.Wang Y, Hu DR, Ren YQ, Yuan XQ, Zhang XH, Pen XJ, Liu DQ. Early Effects of percutaneous radiofrequency ablation for treatment of liver tumors. Chiese Tumor Clin. 2001;28 (10) :737-740.
159.Spies JB, Coyne K, Guaou N, Boyle D, Skyrnarz-Murphy Gonzalves SM.The UFS-QOL, a new disease-specific symptom and health-relatedquality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99: 290-300.
160.Goldberg SN, Livraghi T, Solbiati L, Gazelle GS. In situ ablation of focal hepatic neoplasms. In: Gazelle GS, Saini S, Mueller PR, eds. Hepatobiliary and Pancreatic Radiology: Imaging and Intervention. New York: Thieme, 1997.
161.De Sanctis JT, Goldberg SN, Mueller PR. Percutaneous treatment of hepatic neoplasms: A review of current techniques. Cardiovasc Intervent Radiol. 1998;21:273-296.
162.Nisolle M, Smets M, Malvaux V, Anaf V, Donnez J. Laparoscopic myolysis with the Nd: YAG laser. J Gynecol Surg. 1993;9:95-99.
163.Jourdain O, Roux D, Cambon D, Dallay D. A new method for the treatment of fibromas: Interstitial laser hyperthermia using the Nd: YAG laser. Preliminary study. Eur J Obstet Gynecol Reprod Biol. 1996;64:73-78.
164.Exacoustos C, Zupi E, Marconi D. Ultrasound-assisted laparoscopic cryomyolysis: Two- and three-dimensional findings before, during and after treatment. Ultrasound Obstet Gynecol. 2005;25: 393-400.
165.Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Hum ReprodUpdate.2000;6: 595-602.
166.Marret H, Alonso AM, Cottier JP, Tranquart F, Herbreteau D, Body G (2003) Leiomyoma recurrence after uterine artery embolization. J Vasc Interv Radiol. 14: 1395-1399.
167.Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L(1995) Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod. 10:1795-1796.
168.Chapman R. Treatment of uterine myomas by interstitial hyperthermia.Gynecol Endosc. 1993; 2:227-234.
169.Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89:857-861.
170.Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc. 1998; 5: 289-292.
171.Ciavattini A, Tsiroglou D, Litta P, Vichi M, Tranquilli AL (2006) Pregnancy outcome after laparoscopic cryomyolysis of uterine myomas: report of nine cases. J Minim Invasive Gynecol. 13:141-144.
172.Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol. 1976;39:69-76.
173.Lounsberry W, Goldschmidt V, Linke CA, Walder HJ, Chrzan D. The early histologic changes following electrocoagulation. J Urol. 1961;86: 321-329.
174.Spies JB, Coyne K, Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99: 290-300.
175.Watson NR, Studd JWW, Gamett T. Bone Loss after-hysterectomy with ovarian consevative. Obste Gynecol. 1995;86:72-77.
176.Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Radiology. 1991;178:253-258.
177.Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
178.Choi H, Loyer EM, DuBrow RA. Radiofrequency ablation of liver tumors: assessment of therapeutic response and complications. Radio Graphics. 2001;21:S41-S54.
179.Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, Lee WJ, Lim HK, Nam GJ, Han SS, Kim YH, Park CM, Kim PN, Byun JY. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. RadioGraphics. 2003;23:123-136.
180.Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Intervent Radiol. 2000;11:1069-1075.
181.Llovet JM, Vilana R, BrúC, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, SoléM, Rodés J, Bruix J; Barcelona Clínic Liver Cancer (BCLC) Group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124-1129.
182.Phillips DR, Milim SJ, Nathanson HG, Haselkorn JS. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc. 1997;4:425-433.
183.Chapman R. Treatment of uterine myomas by interstitial hyperthermia. Gynecol Endosc. 1993;2:227-234.
184.Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89:857.
185.Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc. 1998;5:289-292.
186.ter-Hear G,Therapeutic ultrasound,Eur J Ultrasound. 1999,9(1):3-9.
187.Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, Wang ZB. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol. 2002;28:535-542.
188.Zhou XD, Ren XL, Zhang J, He GB, Zheng MJ, Tian X, Li L, Zhu T, ZhangM, Wang L, Luo W. Therapeutic response assessment of high intensity focused ultrasound therapy for uterine fibroid: utility of contrast-enhanced ultrasonography. Eur J Radiol. 2007;62(2):289-94.
189.Farmakides G, Stefanidis K, Paschopoulos M, Mamopoulos M, Lolis D. Uterine artery Doppler velocimetry with leiomyomas. Arch Gynecol Obstet, 1998;262: 53-7.
190.Hynynen K, Chung AH, Colucci V, Jolesz FA. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol. 1996;22(2):193-201.
191.Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics, 2005;25 (Suppl 1):S69-83.
192.Harman M, Zetero?lu S, Sengül M, Etlik O, Arslan H. Uterine leiomyoma embolization: Role of power Doppler ultrasonography. Tani Girisim Radyol. 2003;9(2):240-245.
2. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94:435-38.
3. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly gorwing leiomyoma. Obstet Gynecol. 1994;83:414-18
4. Otubu JA, Buttram VC, Besch NF, Besh PK. Unconjugated Steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol. 1982;143:130-3.
5. Ymarnoto T, Takamoir K, Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res. 1984,16:678-9
6. Brandon DD, Erichson TE, Keenna EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton GM. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995;80:1876-81.
7. Ichimura T, Kawarmura N, Ito F, Minakuchi K, Tsujimura A, Umesaki N, Ogita S. Corerlation between the growth of uterine leiomyomata and estrogen and progensterone receptor content in needle biopsy specimens. Fertil Steril. 1998;70:967-71.
8. Lamminen S, Rantalal, Helin H, Rorarius M, Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gymecol Obstet Invest. 1992;34:111-4.
9. Kawaguchi K, Fuji S, Konishil, Nanbu Y, Nonogaki H, Mori T. Mitoticactivity in uterine leiomyomas during the menstrul cycle. Am J Obstet Gynecol. 1989;160:637-41.
10. Fujii S, Nakashima N, Okamura H. Progesterone-induced smooth muscle-like cells in the subperitoneal nodules produced by estrogen. Experimental approach to leiomyomatosis petronealis disseminate. Am J Obstet Gynecol. 1981;139(2):164-172.
11. Aornica SM, Katzenellenbogen Bs. Porgestrone receptor regulation in uterine cells: Stimulation by estrogen, cuclic adenosine3’5’-monophosphate, and insulin-like growth facter I and suppression by antiestrogens and protein kinase inhabitors. Endocrinoloy 1991;128:2045-52.
12. Yet J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF recetor demonstrable in monolayer cell cultures of myometria and leiomyoma. Fertil Steril. 1991;56:997-1000.
13.郁雯,姜英,王晓玲.子宫肌瘤组织雌孕激素受体和表皮生长因子受体研究肿瘤研究与临床2002;14(4):234-236.
14.甘晓平,李卫平,陈珠萍.表皮生长对子宫肌瘤发生发展的影响.中国实用妇科与产科杂志2000;16(11):677-678.
15. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine orparacrine growth factor for human myometial and leiomyoma cells. Gynecol Obstet Invest. 1999;48:127-132.
16. Gover A, Mukunda BN. Humoral hypercalcemia associated with a uterine fibroid letter. Ann Intern Med. 1999;130(8):702.
17. Nohara A, Ohmichi M, Koike K. Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. Biochem Biophys Res Commun. 1997;238(2):473-474.
18. Ohbuchi H, Nagai K, Yamaguchi M, Ikenoue T, Mori N, Kitamura K, ArakiS, Toshimori K. Endothelin-1 and big endothelin-1 increase in human endometerium during menstruation. Am J Obstet Gynecol. 1995;173(5):1483-90.
19. Pekonen F, Nyman T, Rutnaen EW. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. Mol Cell Endocrino. 1994;103:165-170.
20. Clevenger-Hoeft M, Syrop CH, Stovall DW, Van Voorhis BJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999;94(4):516-20.
21. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Repord Update 1996;2(4):295-306.
22. Stovall JG, Gussak LS. Dysphagia and Chronic Mental Illness: Looking Beyond Hysteria and Broadening the Psychiatric Differential Diagnosis. Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):143-144.
23. Coutinho EM, Maia HS. The contractile response of the human uterus, fallopian tubes, and ovary to prostaglandins in vivo. Fertil Steril. 1971 Sep;22(9):539-43.
24. Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol. 1970 ;23(8):676-80.
25. Strobelt N, Ghidini A, Cavallone M, Pensabene I, Ceruti P, Vergani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med. 1994;13(5):399-401.
26. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol. 2000;95(5):764-9.
27. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinicalpresentation. Am J Obstet Gynecol. 1993;168(1 Pt 1):180-3.
28.徐苓.子宫肌瘤非手术治疗的理论基础及适应症.中国实用妇科与产科杂志2001;17(3):129.
29.李力,子宫肌瘤的性激素治疗.中国实用妇科与产科杂志2001;17 (3):132
30. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993; 76(2):513-517
31. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746-51
32. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women withuterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109:1097-108.
33. Rutgers JL, Spong CY, Sinow R, Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol. 1995;86:386-8.
34. Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyoma in Japanese women. Fertil Steril. 1992;58:66-71
35. Lee WL, Yuan CC, Wang PH. Positron emission tomography and uterine leiomyomas. Gynecol Oncol. 2007;107:593-4.
36. Lee WL, Liu RS, Yuan CC, Chao HT, Wang PH. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography. Fertil Steril. 2001;75:638-9.
37. Ito F, Kawamura N, Ichimura T, Tsujimura A, Ishiko O, Ogita S. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment. Fertil Steril. 2001;75:125-30
38. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993;24:1073-7.
39. Higashijima T, Kataoka A, Nishida T, Yakushiji M. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 1996;68:169-73.
40. Cheng MH, Yu BK, Chang SP, Wang PH. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. J Chin Med Assoc. 2005;68:307-14.
41. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril. 1992;58:413-5.
42. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol. 1994;8:215-22.
43. Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 1990;53:1018-23.
44. Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women-focus on the breast. Taiwan J Obstet Gynecol. 2007;46:127-34.
45. Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonists. Fertil Steril. 1993;60:642-6.
46. De Blok S, Oberye J. Rapid reduction of leiomyoma volume during treatment with the GnRH-antagonist ganirelix. Gynecol Endocrinol. 2001;15:22.
47. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-62.
48. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term Use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5:235-41.
49. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;(4):CD002126.
50. Habelt K, Brosche T, Riedel HH. Symptoms of ovarian failure after hysterectomy in premenopausal women. A retrospective study based on postoperative perception of 245 women. Zentralbl Gynakol 1996; 118(4):206-212.
51. Eltabbakh GH. Effect of surgeon experience on the surgical outcome of laparoscop in surgery for women with endometrial cancer. Gynecol Oncol. 2000;78(1):58-61.
52. Falcone T, Paraiso MF, Mascha E. Prospective random ized clinical trial of laparoscop ically assisted vaginal hysterectomy versus total abdom inal hysterectomy. Am J Obstet Gynecol. 1999;180(4):955-962.
53. Hallez JP. Single-stage total hysteroscopic myomectomies: indications, techniques, and results. Fertil Steril. 1995;63(4):703-8.
54. Polena V, Mergui JL, Perrot N, Poncelet C, Barranger E, Uzan S. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):232-7.
55. Ravina J H, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A, Merland JJ. Arterial embolization to treat uterine myomata. Lancet 1995;346(8976):671-2.
56. Ravina J H, Bouret J H, Ciraru-Vigneron N, Repiquet D, Herbreteau D, Aymard A, le Dreff O, Merland JJ, Ferrand J. Recourse to particular arterial embolization in the treatment of some uterine leiomyoma. Bull Acad Natl Med. 1997;181 (2):233-43.
57. Worthington-Kirsch RL, Popky GL, Hutchins FL. Uterine arterial embolization for the management of leiomyomas: quality-of-life assessment and clinical response. Radiology 1998;208:625-9.
58. Vashisht A, Studd J, Carey A, Burn P. Fatal sepicaemia after fibroid embolisation. Lancet 1999;354 (9175):307-308
59. Dover RW, Torode HW, B riggs GM. Uterine artery embolisation for symptomatic fibroids. Med J Aust. 2000;172(5): 233-236.
60.杨华光,井红鸽,李冰.阔韧带内巨大子宫肌瘤行介入栓塞术导致卵巢坏死的诊治.医学研究生学报2003;16(12): 956-959.
61. Worthington-Kirsch RL, Andrews RT, Siskin GP, Shlansky-Goldberg R, Lipman JC, Goodwin SC, Bonn J, Hovsepian DM. Uterine fibroid embolization: technical aspects. Tech Vasc Interv Radiol. 2002;5 (1):17-34.
62. Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. Laparoscopic leiomyoma coagulation. Am Assoc Gynecol Laparoscop 1996;3(4Suppl):S39
63. Goldfarb H.Laparoscopic coagulation of myoma (myolysis).Obstet Gynecol Clin North Am. 1995;22(4):807-819.
64. Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopi electromyolysis. Am Assoc Gynecol Laparoscop. 1998;5(3):289-292.
65.白广德,谢爱玲,谢桂珍.腹腔镜引导经皮氩氦靶向治疗子宫肌瘤5例.广西中医学院学报2004;7(1):32-34.
66.陈湘云,罗启东.微波治疗脱入阴道的子宫黏膜下肌瘤.中华妇产科1997,32(1).
67.刘平,张俊发,戴秋玲.微波治疗宫颈肌瘤.中华物理医学与康复杂志2000, 22 (6):382.
68. Lynn JG, Fry WJ, Meyers R. The biological application focused ultrasonic waves. Science. 1942;96(2483):119-120.
69. Wu F, Wang ZB, Zhu H, Extracorpo real high in tensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Res Treat. 2005;92: 5160.
70. Uchida T, Baba S, Irie A. Tran srectal high intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyo kika Kiyo 2005;51: 651-658.
71. Ren XL, Zhou XD, Zhang J, He GB, Han ZH, Zheng MJ, Li L, Yu M, Wang L. Extracorporeal Ablation of Uterine Fibroids with High-Intensity Focused Ultrasound Imaging and Histopathologic Evaluation. J Ultrasound Med 2007; 26:201-12.
72. Hynynen K, Chung AH, Colucci V, Jolesz FA. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol, 1996; 22(2):193-201.
73.谢红宁,车艳玲,刘杰.超声引导下瘤内无水乙醇注射治疗子宫肌瘤的初步研究.中国实用妇科与产科杂志,2000,16(4):225.
74. Niu H, Simari RD, Zimmermann EM and Christman GM (1998) Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet Gynecol 91,735-740.
75. Rai R, Barakat O, Rose J, Manas D. Role of radiofrequency ablation in multimodality management of unresectable liver tumours. J Gastrointest Surg. 2003;7:263-264.
76. Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, Griffey SM. Radiofrequeney ablation of breast caneer: first report of emerging technology. Arch Surg. 1999;134(10):064-1068.
77.乔清理.组织消融一般模型的建立与其温度分布的分析与解析计算中国生物医学.工程学报, 2002;21(1):74-78
78. Diekso J, Calder wood S, Storm F. Thermosensitivity of neoplastic in tissues in vivo. Hall Medical Publisher l983,63-140.
79. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227(4):559-65.
80. McGahan JP, Griffery SM, Schneider PD, Brock JM, Jones CD, Zhan S.. Radiofrequency electrocautery ablation of mammary tissue in swine. Radiology. 2000;217:471-6.
81. Cuschieri A, Bracken J, Boni L. Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumors. Endoscopy. 1999;31(4):318-21.
82. Pearson SA, Lzzo F, Fleming RY. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178:592-9.
83. Walther MM, Shawker TH, Libutti SK. A phase II study of radiofrequency interstitial tissue ablation of localized renal tumors. J Urol. 2000;163:1424.
84. Lencioni R, Goletti O, Amillotta N. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial. Eur Radiol 1998;8(7):1205-1211.
85. de Baere T, Denys A, Wood BJ. Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol 2001;176:187–192
86. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169–S171
87. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangio carcinomavariants. J Gastroenterol Hepatol 2002;17(4):401-405.
88. Bowles BJ, Machi J, Limm WM. Safety and efficacy of radio-frequency thermal ablation in advanced liver tumors. Arch Surg 2001;136:864-869.
89. Gillams AR, Lees WR. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:656-661.
90. Parikh AA, Curley SA, Fornage BD. Radiofrequency ablation of hepatic metastases. Semin Oncol 2002;29(2):168-182.
91. McGahan JP, Dodd GD. Radiofrequency ablation of the liver: current status. Am J Roent 2001;176:3-16.
92. Topham C, Adam R. Oncosurgery: a new reality in metastatic colorectal carcinoma. Semin Oncol 2002;29(5 Suppl 15):3-10.
93. McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990;25:267-270.
94. Rossi S, Stasi MD, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CTS, ilverman DE, Buscarini L. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR 1996;167:759-768.
95. Rossi S, Buscarini E, Garbagnati F, Stasi MD, Quaretti P, Rago M, Zangrandi A, Andreola S, Silverman D, Bsucarini L. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR 1998;170:1015-1022.
96. Buscarini L, Buscarini E, Stasi MD, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 2001;11:914-921.
97. Rossi S, Garbagnati F, RosaL, Azzaretti A, Belloni G, Quaretti P. Radiofrequency thermal ablation for treatment of hepatocellular carcinoma. Int J Clin Oncol 2002;7:225-235.
98. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-661.
99. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-166.
100.D'Ippolito G, Goldberg SN. Radiofrequency ablation of hepatic tumors. Tech Vasc Interv Radiol 2002;5(3):141-155.
101.Goldberg SN, Solbiati L. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001;34:609-611.
102.Livraghi T. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001;34:608-611.
103.Livraghi T, Solbiati L, Meloni MF. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
104.Jacomides L, Ogan K, Watumull L. Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol 2003;169:49-53.
105.Pavlovich CP, Walther MM, Choyke PL. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol 2002;167:10-5.
106.Gervais DA, McGovern FJ, Arellano RS. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003;226:417-424.
107.Pinto CH, Taminiau AH, Vanderschueren GM. Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol 2002;179:1633-1642.
108.Vanderschueren GM, Taminiau AH, Obermann WR. Osteoid osteoma: clinical results with thermocoagulation. Radiology 2002;224:82-86.
109.Callstrom MR, Charboneau JW, Goetz MP. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 2002;224:87-97.
110.Callstrom MR, Charboneau JW, Goetz MP. Percutaneous CT/US-guided radiofrequency ablation of painful metastases involving bone: a multicenter international study. Radiol Soc North Am Annual Meeting. 2002
111.Sewell PE Jr. Percutaneous radiofrequency ablation of primary and secondary pulmonary malignancies using CT guidance. Radiol Soc North Am Annual Meeting. 2002
112.Lee J, Jin G, Lee Y. CT-guided transthoracic radiofrequency ablation formedically inoperable stage I non-small cell lung cancer. Radiol Soc North Am Annual Meeting. 2002
113.Rose SC, Fotoohi M, Levin DL. Cerebral microembolization during radiofrequency ablation of lung malignancies. J Vasc Interv Radiol. 2002;13:1051-1054.
114.Izzo F, Thomas R, Delrio P. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer. 2001;92:2036-2044.
115.Wood BJ, Abraham J, Hvizda JL. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554-560
116.Pacak K, Fojo T, Goldstein DS. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001;93:648-649.
117.Wu JS, Wong R, Johnston M. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594-605.
118.冯忻,刘海鹰,赵营,谭小军,陈力排.多弹头射频治疗妇科肿瘤的尝试.广东医学. 2001; 22 (8):692-693.
119.邱学华,邓黎,李月英,吴蕾,王新玲,高静.射频消融子宫肌瘤的病理变化.第四军医大学学报. 2003;24(14):1301-1303.
120.曹树军,曹淑彬,陈双郧,杨卫疆,张春莲,王梅,何琳,王斌.射频消融治疗子宫肌瘤的安全性研究.郧阳医学院学. 2002;21(3):132-135.
121.Bergam ini V, Ghezzi F, Crom i A, Bellini G, Zanconato G, Scarperi S, Franchi M. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. Am J Obstet Gynecol. 2005;192(3):768-773.
122.汤晓秋,刘广月.射频消融治疗子宫肌瘤196例报告.江苏大学学报(医学版). 2003;13 (4): 340-341.
123.宋雯霞,罗新,吴秀枝,常明伟.射频消融对子宫肌瘤组织病理变化及雌、孕激素受体表达的影响.郧阳医学院学报. 2002,21(5):257-260.
124.Phipps JH, Lewis BV, Roberts T, Prior MV, Hand JW, Elder M, Field SB. Treatment of functional menorrhagia by radiofrequeney-induced thermal endometrial ablation. Lancet, 1990;335(8686):374-6.
125.Phipps JH, Lewis BV, Prior MV, Roberts T. Experimental and clinical studies with radiofrequency-induced thermal endometrial ablation for functional menorrhagia: Obstet Gyneeol. 1990;76(5Ptl):876-81.
126.phipps JH, Smith T, Dymek P, Hesp R, Lewis BV. Validation of a method of treating menorrhagia by endometrial ablation. Clin Phys Physiol Meas.1992;13(3):273-80.
127.Silvemagel SW, Harshbarger KE, Shevlin DW. Postoperative granulomas of the endometrium: histological features after endometrial ablation. Ann Diagn Pathol.1997;1(2):82-90.
128.Dequesne JH, Gallinat A, Garza-Lea JG, Sutton CJ, van der Pas HF, Wamsteker K, Chandler JG. l. Int J Fertil Womens Med. 1997;42(5):311-18.
129.宋学红,迟闺珠,于秀梅,高居中.射频消融术治疗宫颈糜烂的疗效观察.中华物理医学杂志. 1996,18(3):155-156.
130.王共先,熊礼生,梁绮霞,鲁伟明,刘群.腔内射频热治疗慢性宫颈炎.江西医学. 1998, 23(l):3-4.
131.李庆丰,区海,钟沼涛.应用射频治疗子宫颈糜烂.中华妇产科杂志. 2000, 35(3)184-185.
132.BianeoV, Erba P, Remotti G. Florid vulvar condylomatosi Comparison of therapeutic schedules. Ann Ostet Gineeol Med perinat, 1991;112(4):247-56
133.Zaza M, Grassi , Mardjonovic A, Valli E, FarnéC, Romanini C. The use of eleetrosurgery in the treatment of extra-cervical genital condylomatosis, Minerva Gineeol, 1998;50(9):367-71.
134.Challenor R,Alexander I. A five-year audit of the treatment of extensive anogenital Warts by day case eleetrosurgery under general anaesthesia. Int J STD AIDS. 2002;13(11):786-9.
135.Manganill PD, Sueoka BL, Valntine DR. A bipolar radiofrequency catheter fails to occlude a feline uterine horn: A model for fallopian tube occlusion. Am Assoe Gynecol Laparosc. 1998;5(3):269-73.
136.Hurst BS,Ryan T,Thomsen S,Lawes K. ComPuter-controlled bipolar endotubal Sterilization is sueeessful in a rabbit model. Fertil Steril. 1999,71(4):765-70.
137.Kuscu E, Duran HE, Zeyneloglu HB, Demirhan B, Bagis T, Saygili E. The effect surgical sterilization on ovarian function: a rat model. Eur J Obstet Gynecol Reprod Biol. 2002;100(2):204-7.
138.Buscarini L, Buscarini E, Stasi MD, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11:914-921.
139.Livraghi T, Solbiati L, Meloni MF. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
140.Fontana RJ, Hamidullah H, Nghiem H. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl Surg. 2002;8:1165-1174.
141.Wiersinga WJ, Jansen MC, Straatsburg IH. Lesion progression with time and the effect of vascular occlusion following radiofrequency ablation ofthe liver. Br J Surg. 2003;90:306-312.
142.Yamasaki T, Kurokawa F, Shirahashi H. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer. 2002;95:2353-2360.
143.Goldberg SN, Ahmed M, Gazelle GS. Radio-frequency thermal ablation with NaCl solution injection: effect of electrical conductivity on tissue heating and coagulation-phantom and porcine liver study. Radiology. 2001;219:157-165.
144.Kitamoto M, Imagawa M, Yamada H. Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without embolization. Am J Roentgenol. 2003;181:997-1003.
145.Chopra S, Dodd GD 3rd, Chintapalli KN. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol.2001;177:381-387.
146.Anderson GS, Brinkmann F, Soulen MC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192-197.
147.Cioni D, Lencioni R, Rossi S. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power doppler sonography to assess treatment outcome. AJR Am J Roentgenol. 2001;177:783-788.
148.黄荷风,胡林姿.子宫内分泌.外医学妇产科分. 1994,21(5):263-266.
149.Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC. Radiofrequency ablation of solid tumors. Cancer. 2001;7(2)95-102.
150.曹泽毅,主编,中华妇产科学,第1版北京:人民卫生出版社. 1999:1802
151.Bergqvist A, Nejaty H, Fr?ysa B, Bruse C, Carlberg M, Sj?blom P, S?der O. Production of interleukinslbeta,6 and 8 and tumor necrosis factor alpha in separated and cultured endometrial and endometriotic stromal and epithelial cells. Gynecol Obstet Invest. 2000;50(1):1-6.
152.Witz CA, Takahashi A, Montoya-Rodriguez IA, Cho S, Schenken RS. Expression of the alpha 2 beal and alpha3 betal integrins at the surface of mesothelial cells: a potential attachment site of endometrial cell, Fertil steril. 2000;74(3):579-584.
153.黄舒娥,刘运科,赵慧娟,龚慧芳.全子宫切除术对妇女血脂、血液流变学的影响.中国现代医学杂志. 1997;7(10):18-19.
154.范引侠,吴静,彭慧霞.子宫切除术后远期卵巢功能变化的临床观察.陕西医学杂志. 2002;31(6):392-394.
155.邓敏,王祥珍.子宫肌瘤全子宫切除术后性心理障碍研究.湖北医科大学学报. 2000;21(3):236-237.
156.Wang GX, Xion LS, Peng SP. Pathological changes and changes in expression of PSA, SR of prostatic tissue induce by radio-frequency hyperthermia. Chin J Urol 1997;18(11):643-6.
157.Qiao QL, Wang MS, Zhu YS. A general model for human tissue ablation and its analytical calculation of temperature distribution. China J Biomed Eng. 2002;21(1):74-8.
158.Wang Y, Hu DR, Ren YQ, Yuan XQ, Zhang XH, Pen XJ, Liu DQ. Early Effects of percutaneous radiofrequency ablation for treatment of liver tumors. Chiese Tumor Clin. 2001;28 (10) :737-740.
159.Spies JB, Coyne K, Guaou N, Boyle D, Skyrnarz-Murphy Gonzalves SM.The UFS-QOL, a new disease-specific symptom and health-relatedquality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99: 290-300.
160.Goldberg SN, Livraghi T, Solbiati L, Gazelle GS. In situ ablation of focal hepatic neoplasms. In: Gazelle GS, Saini S, Mueller PR, eds. Hepatobiliary and Pancreatic Radiology: Imaging and Intervention. New York: Thieme, 1997.
161.De Sanctis JT, Goldberg SN, Mueller PR. Percutaneous treatment of hepatic neoplasms: A review of current techniques. Cardiovasc Intervent Radiol. 1998;21:273-296.
162.Nisolle M, Smets M, Malvaux V, Anaf V, Donnez J. Laparoscopic myolysis with the Nd: YAG laser. J Gynecol Surg. 1993;9:95-99.
163.Jourdain O, Roux D, Cambon D, Dallay D. A new method for the treatment of fibromas: Interstitial laser hyperthermia using the Nd: YAG laser. Preliminary study. Eur J Obstet Gynecol Reprod Biol. 1996;64:73-78.
164.Exacoustos C, Zupi E, Marconi D. Ultrasound-assisted laparoscopic cryomyolysis: Two- and three-dimensional findings before, during and after treatment. Ultrasound Obstet Gynecol. 2005;25: 393-400.
165.Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Hum ReprodUpdate.2000;6: 595-602.
166.Marret H, Alonso AM, Cottier JP, Tranquart F, Herbreteau D, Body G (2003) Leiomyoma recurrence after uterine artery embolization. J Vasc Interv Radiol. 14: 1395-1399.
167.Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L(1995) Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod. 10:1795-1796.
168.Chapman R. Treatment of uterine myomas by interstitial hyperthermia.Gynecol Endosc. 1993; 2:227-234.
169.Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89:857-861.
170.Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc. 1998; 5: 289-292.
171.Ciavattini A, Tsiroglou D, Litta P, Vichi M, Tranquilli AL (2006) Pregnancy outcome after laparoscopic cryomyolysis of uterine myomas: report of nine cases. J Minim Invasive Gynecol. 13:141-144.
172.Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol. 1976;39:69-76.
173.Lounsberry W, Goldschmidt V, Linke CA, Walder HJ, Chrzan D. The early histologic changes following electrocoagulation. J Urol. 1961;86: 321-329.
174.Spies JB, Coyne K, Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99: 290-300.
175.Watson NR, Studd JWW, Gamett T. Bone Loss after-hysterectomy with ovarian consevative. Obste Gynecol. 1995;86:72-77.
176.Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Radiology. 1991;178:253-258.
177.Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
178.Choi H, Loyer EM, DuBrow RA. Radiofrequency ablation of liver tumors: assessment of therapeutic response and complications. Radio Graphics. 2001;21:S41-S54.
179.Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, Lee WJ, Lim HK, Nam GJ, Han SS, Kim YH, Park CM, Kim PN, Byun JY. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. RadioGraphics. 2003;23:123-136.
180.Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Intervent Radiol. 2000;11:1069-1075.
181.Llovet JM, Vilana R, BrúC, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, SoléM, Rodés J, Bruix J; Barcelona Clínic Liver Cancer (BCLC) Group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124-1129.
182.Phillips DR, Milim SJ, Nathanson HG, Haselkorn JS. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc. 1997;4:425-433.
183.Chapman R. Treatment of uterine myomas by interstitial hyperthermia. Gynecol Endosc. 1993;2:227-234.
184.Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89:857.
185.Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc. 1998;5:289-292.
186.ter-Hear G,Therapeutic ultrasound,Eur J Ultrasound. 1999,9(1):3-9.
187.Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, Wang ZB. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol. 2002;28:535-542.
188.Zhou XD, Ren XL, Zhang J, He GB, Zheng MJ, Tian X, Li L, Zhu T, ZhangM, Wang L, Luo W. Therapeutic response assessment of high intensity focused ultrasound therapy for uterine fibroid: utility of contrast-enhanced ultrasonography. Eur J Radiol. 2007;62(2):289-94.
189.Farmakides G, Stefanidis K, Paschopoulos M, Mamopoulos M, Lolis D. Uterine artery Doppler velocimetry with leiomyomas. Arch Gynecol Obstet, 1998;262: 53-7.
190.Hynynen K, Chung AH, Colucci V, Jolesz FA. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol. 1996;22(2):193-201.
191.Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics, 2005;25 (Suppl 1):S69-83.
192.Harman M, Zetero?lu S, Sengül M, Etlik O, Arslan H. Uterine leiomyoma embolization: Role of power Doppler ultrasonography. Tani Girisim Radyol. 2003;9(2):240-245.